Compare Archer-Daniels-Midland Co (ADM) vs Axogen Inc (AXGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Axogen Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.38 (market cap $38.78B), while Axogen Inc trades at $48.64 (market cap $2.61B). The key difference: Archer-Daniels-Midland Co is far larger — about 14.9× Axogen Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| ADM | AXGN | |
|---|---|---|
Market Cap | $38.78B | $2.61B |
Sector | Consumer Staples | Technology |
52-Week High | $87.32 | $48.48 |
52-Week Low | $56.00 | $14.16 |
Enterprise Value | $47.03B | $2.52B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $80.49, up 5.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue has declined from $101.6B in 2022 to $80.3B in 2025, but net income margin improved to 2.16% in 2025. The company raised its 2026 outlook after Q2 results, citing biofuels and nutrition strength. Valuation ratios include a P/E of 21.98 and P/S of 0.48, indicating potential undervaluation relative to earnings growth prospects.
Outlook is positive with analyst consensus price target of $88.00, though execution risks and competitive pressures remain. Investment opportunity lies in continued margin expansion and biofuel demand, while risks include volatile commodity prices and debt levels. The stock offers a dividend yield supported by 379 consecutive quarterly payments.
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →
